N/A
Manufactured by E.R. Squibb & Sons, L.L.C.
27,247 FDA adverse event reports analyzed
Last updated: 2026-04-14
ATAZANAVIR is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by E.R. Squibb & Sons, L.L.C.. The most commonly reported adverse reactions for ATAZANAVIR include DRUG INTERACTION, DEPRESSION, FOETAL EXPOSURE DURING PREGNANCY, ANXIETY, MATERNAL EXPOSURE DURING PREGNANCY. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ATAZANAVIR.
Out of 14,254 classified reports for ATAZANAVIR:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 27,247 FDA FAERS reports that mention ATAZANAVIR. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INTERACTION, DEPRESSION, FOETAL EXPOSURE DURING PREGNANCY, ANXIETY, MATERNAL EXPOSURE DURING PREGNANCY, PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list E.R. Squibb & Sons, L.L.C. in connection with ATAZANAVIR. Always verify the specific product and NDC with your pharmacist.